Patent US4748023A successfully refreshed from Google Patents.
US4748023A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content
Assignee: Egyt Gyogyszervegyeszeti Gyar
•
Filing: 1984-01-25
•
Granted: 1988-05-31
•
Expires: 2004-01-25
Abstract
Abstract PCT No. PCT/HU84/00006 Sec. 371 Date Aug. 27, 1984 Sec. 102(e) Date Aug. 27, 1984 PCT Filed Jan. 25, 1984 PCT Pub. No. WO84/02843 PCT Pub. Date Aug. 2, 1984.The invention relates to a process for the preparation of sustained release solid pharmaceutical compositions having an active ingredient content of at least 80% and possessing a structure which loosens in aqueous medium but does not disintegrate to discrete particles within 4 hours which comprises coating the particles of the active ingredient in a liquid medium with a water insoluble polymer-preferably with an ethyl cellulose polymer film-and thereafter admixing the coated crystals with at least one disintegrating agent being capable of swelling in aqueous medium and other auxiliary agents conventionally used in pharmaceutical industry and pressing the mixture into tablets. The advantage of the process of the present invention is that it is readily feasible with a very wide range of active ingredients and provides sustained release tablets having a high active ingredient content.
Inventors
- 👤 Eva Tamas
- 👤 Pal Fekete
- 👤 Tibor Kovacs
- 👤 Denes Bezzegh
- 👤 Ilona Bor nee Baumgartner
- 👤 Zoltan Toth
- 👤 Katalin Zukovics nee Sumeg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 08:36
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/20; A61K9/2072; A61K9/2077; A61K9/2081
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
197 words
A compressed relatively large single sustained release and dosage unit tablet which consists essentially of: (a) at least 80% by weight of 100 to 500 mg. of at least one pharmacologically active ingredient, encapsulated in (b) an effective amount of a pharmaceutically acceptable water insoluble polymer for microencapsulating said active ingredient and for retarding the dissolution of the active ingredient within the human body for a predetermined period of time, said effective amount being from about 2% to about 18% by weight of said tablet, and admixed therewith (c) an effective amount of from about 0.9% to about 25% by weight of the tablet of a pharmaceutically acceptable, water swellable disintegrating agent for loosening the structure of the compressed tablet in water or like body fluid without disintegration of the tablet into discrete particles for a period of at least 4 hours, said tablet having been compressed at a predetermined force effective cooperatively with said polymer and said disintegrating agent to form a cross-linked matrix structure from the walls of the microcapsules during pressing a matrix structure which loosens upon aqueous swelling, to regulate the release at a predetermined rate of said active ingredient from said tablet.
Claim 2
Dependent Claim
197 words
A compressed relatively large single sustained release and dosage unit tablet which consists essentially of: (a) at least 80% by weight of 100 to 500 mg. of at least one pharmacologically active ingredient, encapsulated in (b) an effective amount of a pharmaceutically acceptable water insoluble polymer for microencapsulating said active ingredient and for retarding the dissolution of the active ingredient within the human body for a predetermined period of time, said effective amount being from about 2% to about 18% by weight of said tablet, and admixed therewith (c) an effective amount of from about 0.9% to about 25% by weight of the tablet of a pharmaceutically acceptable, water swellable disintegrating agent for loosening the structure of the compressed tablet in water or like body fluid without disintegration of the tablet into discrete particles for a period of at least 4 hours, said tablet having been compressed at a predetermined force effective cooperatively with said polymer and said disintegrating agent to form a cross-linked matrix structure from the walls of the microcapsules during pressing a matrix structure which loosens upon aqueous swelling, to regulate the release at a predetermined rate of said active ingredient from said tablet.
Claim 3
Dependent Claim
20 words
The tablet of claim 1, wherein said disintegrant comprises from about 0.9 to about 25% by weight of the tablet.
Claim 4
Dependent Claim
16 words
The tablet of claim 1, wherein said polymer is a cellulosic, butyral, butylene, or vinyl polymer.
Claim 5
Dependent Claim
20 words
The tablet of claim 3, wherein said polymer is ethyl cellulose, cellulose acetate, vinyl butyral, isobutylene, or vinyl acetate polymer.
Claim 6
Dependent Claim
27 words
The tablet of claim 1, wherein said disintegrant is at least one of microcrystalline cellulose, potato starch, carboxymethyl starch, formaldehyde casein, crosslinked polyvinylpyrrolidone, magnesium stearate, and lactose.
Claim 7
Dependent Claim
23 words
The tablet of claim 1, wherein the active ingredient is L-alpha methyl dopa, trimethoprim, theophylline, potassium chloride, or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
54 words
The tablet of claim 5, wherein said disintegrant comprises from about 0.9 to about 25% by weight of the tablet, said polymer is an ethyl cellulose, cellulose acetate, vinyl butyral, isobutylene, or vinyl acetate polymer, and the active ingredient is L-alpha methyl dopa, trimethoprim, theophyilline, or potassium chloride, or a phamaceutically acceptable salt thereof.
References Cited (Backward Citations)
US2996431A
Cited
US2853420A
Cited
US3155590A
Cited
US3341416A
Cited
US3488418A
Cited
US3524910A
Cited
US3557279A
Cited
US3703576A
Cited
GB1380171A
Cited
US3909444A
Cited
US3891570A
Cited
US3951851A
Cited
US3860733A
Cited
US3922338A
Cited
US4113816A
Cited
US4415547A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-05-31 | 1991-11-30 | 1992-05-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-05-31 | 1995-11-30 | 1996-05-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-05-31 | 1999-11-30 | 2000-05-31 | $7700.00 | Window Closed / Lapsed |